Research programme: anti-inflammatory biologics topical - Rogne Bioscience

Drug Profile

Research programme: anti-inflammatory biologics topical - Rogne Bioscience

Alternative Names: C 15; Chemerin 15; RON-2315

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Oxford
  • Developer Rogne Bioscience; University of Oxford
  • Class Peptides
  • Mechanism of Action Immunosuppressants; Interleukin 12 inhibitors; Interleukin 23 inhibitors; NF-kappa B modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psoriasis
  • No development reported Cardiovascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in United Kingdom (Topical)
  • 31 Jul 2014 Anti-inflammatory peptides licensed to Rogne Bioscience worldwide
  • 01 Jan 2014 Preclinical trials in Psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top